Aegerion Pharmaceuticals, Inc.

• Too Many Questions Make This Thursday Mover a Sell

  By Brian Nichols - May 19, 2013 | Tickers: ACAD, AEGR, SNY

  Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR) rallied an incredible 31.37% on Thursday after a series of bullish notes that painted a clearer picture for its newly approved (rare-cholesterol disease) drug Juxtapid. While the company’s current market capitalization of $1.75 billion suggests that Aegerion has a potential blockbuster on its hand, the reality is not quite so bullish.

  What created the movement?

  Aegerion Pharmaceuticals had previously reported that more »

• 3 Companies Insiders Love

  By Mohsin Saeed - March 28, 2013 | Tickers: AEGR, DOLE, JNS

  An interesting method of assessing the direction a stock can take is by monitoring insider purchases. This is because company insiders hold information about catalysts and industry trends, which is not available to other investors. Institutional investors also have vast resources at their disposal to assess the potential of stocks.

  This makes following insider and institutional buying trends an effective investment strategy. The following few companies have seen significant insider more »

• Insider Siren: Should We Follow the “Whales” Into These Stocks?

  By Brian Gorban - January 30, 2013 | Tickers: AEGR, TST

  Every person involved in the stock market will tell you time and time again that being able to outperform the general market is no easy feat. In fact, 80% of fund managers year in and year out underperform the S&P 500 and has people wondering what is a strategy worth using? One strategy that has proven to be effective over time in determining whether a stock is moving higher more »

• Hedge Funds Are Snapping Up These Stocks

  By Meena Krishnamsetty - January 18, 2013 | Tickers: AEGR, CPWR, LOGM, MRTN, RIG

  The most up-to-date publicly available information on hedge funds comes from 13D and 13G filings, which take place shortly after a fund or other institutional investor owns over 5% of a stock’s outstanding shares (or makes changes to that position at a later date), in addition to any other public disclosures made by the funds themselves or the company involved. We don’t recommend that every single investment by more »

• Better Cancer Treatment: Partnerships and Dividends

  By Josef Ray Dagatan - January 17, 2013 | Tickers: AEGR, AZN, ISIS

  The quality of life that we live is determined in part by how healthy our physical being is. All of us get sick at one time or another, for which we consult a doctor who prescribes a medicine that helps us to regain our health. But as we all know, sicknesses such as cancer and other autoimmune diseases cannot be cured by over-the-counter drugs. Drugs for these kinds of ailments more »